Genmab — Marts 2024
-
interesting thoughts. Nice with some alternative view building some perspective. Thx
-
-
Mentioning ibrutinib I hope Janssen could be interested in Nurix´ BTK degrader NX5148 and maybe also NX2127 to overtake Ibrutinibs place. Both Abbvie and Beigene have their own BTK degrader in the clinic but Nurix is probably still in front. Nurix needs BP to run all the clinical trials needed and to keep Abbvie and Beigene at bay.
-
Er det MRD som kriterie i alle linier, der bliver talt om? Eller er det “blot” i de sene linier?
-
Well, han klagede jo selv over den hårde tid, hvor han blev nødt til at rejse med concorden. Siden forsvandt det fly, og kommerciel første klasse blev mindre behagelig. Nu kommer der vist nye fly i condordeklassen - og hån glæder sig til den komfort. The best is yet to come
-
Uden skyggen af kliniske data, er det den mest gratis omgang nogensinde
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind